Start for free
Start for free
KC

KVP Capital

Description

KVP Capital is an Investment firm.

Investor Profile

KVP Capital has made 7 investments, with 2 in the past 12 months and 14% as lead.

Stage Focus

  • Post Ipo Equity (86%)
  • Seed (14%)

Country Focus

  • United States (86%)
  • Ireland (14%)

Industry Focus

  • Biotechnology
  • Biopharma
  • Life Science
  • Oncology
  • Clinical Trials
  • Therapeutics
  • Information Technology
  • Manufacturing
  • Pharmaceutical
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does KVP Capital frequently co-invest with?

OrbiMed
OrbiMed
North America, New York, United States, New York
Co-Investments: 2
Venrock Healthcare Capital Partners
Venrock Healthcare Capital Partners
North America, California, United States, Palo Alto
Co-Investments: 2
AC
Acuta Capital Partners
North America, California, United States, Belmont
Co-Investments: 6
RTW Investments
RTW Investments
North America, New York, United States, New York
Co-Investments: 2
Ally Bridge Group
Ally Bridge Group
Asia, Hong Kong Island, Hong Kong, Hong Kong
Co-Investments: 2
Avoro Capital Advisors
Avoro Capital Advisors
North America, New York, United States, New York
Co-Investments: 5
Vivo Capital
Vivo Capital
North America, California, United States, Palo Alto
Co-Investments: 3
Affinity Asset Advisors
Affinity Asset Advisors
North America, New York, United States, New York
Co-Investments: 1
Invus
Invus
North America, New York, United States, New York
Co-Investments: 2

What are some of recent deals done by KVP Capital?

Aadi Bioscience

Pacific Palisades, California, United States

Aadi Bioscience develops a potentially mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases.

BiopharmaBiotechnologyLife ScienceOncology
Post Ipo EquityMar 4, 2025
Amount Raised: $100,000,000
Aadi Bioscience

Pacific Palisades, California, United States

Aadi Bioscience develops a potentially mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases.

BiopharmaBiotechnologyLife ScienceOncology
Post Ipo EquityDec 20, 2024
Amount Raised: $100,000,000
Tourmaline Bio

New York, New York, United States

Tourmaline Bio is a clinical biotechnology company developing transformative medicines to dramatically improve and prevent immune diseases.

BiotechnologyClinical TrialsTherapeutics
Post Ipo EquityOct 19, 2023
Amount Raised: $75,000,000
Aadi Bioscience

Pacific Palisades, California, United States

Aadi Bioscience develops a potentially mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases.

BiopharmaBiotechnologyLife ScienceOncology
Post Ipo EquitySep 22, 2022
Amount Raised: $72,500,000
Tourmaline Bio

New York, New York, United States

Tourmaline Bio is a clinical biotechnology company developing transformative medicines to dramatically improve and prevent immune diseases.

BiotechnologyClinical TrialsTherapeutics
SeedMay 1, 2022
Aadi Bioscience

Pacific Palisades, California, United States

Aadi Bioscience develops a potentially mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases.

BiopharmaBiotechnologyLife ScienceOncology
Post Ipo EquityAug 26, 2021
Amount Raised: $154,999,876
Avadel Pharmaceuticals

Dublin, Dublin, Ireland

Avadel is a biopharmaceutical company focused on transforming medicines to transform lives.

BiotechnologyInformation TechnologyManufacturingPharmaceutical
Post Ipo EquityFeb 21, 2020
Amount Raised: $65,000,000
c-shape-1
c-shape-2

Ready to Raise Capital?

Founders in our network have raised from Y Combinator, Sequoia, a16z, and more. You could be next.

Find investors

Pages

Find investorsPricing

Free tools

Pre-Money and Post-Money Valuation Calculator